Scope and Claims Analysis for US Patent 7,521,423 (Exenatide/Exendin-4 Composition) and the US Patent Landscape

United States Patent 7,521,423 claims a pharmaceutical composition defined by (i) an exendin-4 peptide with the amino-acid sequence of SEQ ID NO. 2, (ii) a narrow quantitative dose range expressed “based on a 70 kg patient,” and (iii) specific formulation components selected from buffer/isotonicity/carrier sets. The independent claim structure is formulation-centric rather than device- or use-centric, and the claim coverage is broad on administration routes (in dependent claims) while also narrowing in specific dependent embodiments (e.g., acetate buffer; mannitol/sorbitol; subcutaneous injection; daily-dose regimes).

What does US Patent 7,521,423 claim, and how broad is the coverage?

Core claim architecture: composition with defined peptide + formulation excipient sets

The independent claim (Claim 1) is a pharmaceutical composition comprising:

Exendin-4 peptide comprising SEQ ID NO. 2 (dose specified as 0.001 mg to 1 mg per 70 kg patient)
Pharmaceutically acceptable buffer
Pharmaceutically acceptable isotonicity agent
Pharmaceutically acceptable carrier

Breadth drivers

“Pharmaceutically acceptable buffer/isotonicity agent/carrier” in Claim 1 is open-ended.
The peptide identity is anchored to SEQ ID NO. 2 (sequencing constraint).
Dose is range-limited: 0.001 mg–1 mg per 70 kg.

Key narrowing features

The formulation must include all three categories: buffer + isotonicity agent + carrier.
The quantitative peptide amount must fall inside the 0.001–1 mg per 70 kg range (expressed in the claims, not just in examples).

Claim 10 adds isotonicity selection narrowing

Claim 10 replaces the generic isotonicity category with an explicit list:

Isotonicity agent selected from: sodium chloride, dextrose, boric acid, sodium tartrate, propylene glycol, a polyol, and combinations.

It also keeps buffer as “pharmaceutically acceptable buffer.” This makes Claim 10 narrower than Claim 1 on isotonicity agent selection, but it is still wide because the list includes common parenteral and aqueous excipients and “a polyol.”

Claim 22 is an even more constrained “three-part” composition

Claim 22 requires:

Exendin-4 peptide (SEQ ID NO. 2) 0.001 mg–1 mg per 70 kg
Mannitol or sorbitol or combination
Acetate buffer

This is the most product-composition-like constraint in the set because it fixes both the isotonicity agent and buffer family.

Claim 29 is directed to subcutaneously injectable formulations with explicit aqueous carrier

Claim 29 requires a subcutaneously injectable pharmaceutical composition comprising:

Exendin-4 peptide (SEQ ID NO. 2) 0.001 mg–1 mg per 70 kg
Mannitol or sorbitol or combination
Acetate buffer
Pharmaceutically acceptable aqueous carrier

This claim is narrower than Claim 22 (administration route + “aqueous carrier” language), but it better matches a “finished dosage form” scenario.

What exendin-4 peptide is covered, and what does SEQ ID NO. 2 do legally?

Peptide scope is sequence-defined, not brand-defined

All claims you listed require:

“an exendin-4 peptide which comprises the amino acid sequence of SEQ ID NO. 2”

This makes the key infringement question sequence match at the amino-acid level (or at least “comprises” language potentially capturing variants that still contain the sequence, depending on how SEQ ID NO. 2 is interpreted in the patent specification).

Is exendin-4 “acid” or “amide” included?

Claims 17 and 23 add:

exendin-4 acid and/or exendin-4 amide

That expands coverage to specific terminal modifications or forms (as recited in the claims), while the peptide anchor remains SEQ ID NO. 2.

What is the dose range in US 7,521,423, and how can it affect infringement?

Dose term is “based on a 70 kg patient”

Across Claims 1, 10, 22, 24, 27, 29, and 32, the peptide amount is specified as:

from 0.001 mg based on a 70 kg patient to 1 mg based on a 70 kg patient

Important legal impact:

If a generic or competitor product’s labeled dose (and/or its composition’s calculated per 70 kg amount) falls outside 0.001–1 mg, these claims may not be met.
Formulators often express dose per unit (e.g., per injection pen or vial). A doctrine of equivalence analysis and claim construction around “based on a 70 kg patient” can matter in litigation, but the claim text is still range-constrained.

Lower bound is extremely low; upper bound is modest

This range can cover both low-dose escalation protocols and minimal-dose fixed regimens. The existence of dependent claims about single vs divided daily dosing suggests the patentee anticipated real-world dosing schedules rather than only a one-time administration.

Which buffers and isotonicity agents are explicitly protected?

Acetate buffer is protected via multiple dependent claims

Claim 2: buffer is an acetate buffer (dependent on Claim 1)
Claim 14: buffer is an acetate buffer (dependent on Claim 10)
Claim 22 includes acetate buffer as a required component
Claim 29 includes acetate buffer as a required component

This elevates acetate-buffer versions from “generic buffer” territory (Claim 1/10) into specifically named territory.

Mannitol and sorbitol are explicitly protected

Claim 3: isotonicity agent is mannitol, sorbitol, or combination (dependent)
Claim 12: isotonicity agent is a polyol
Claim 13: polyol is mannitol and/or sorbitol (dependent)
Claims 22 and 29 require mannitol/sorbitol as a required set

This creates a strong infringement pathway for formulations using mannitol/sorbitol in acetate-buffered exendin-4 systems.

What carriers and excipient systems are protected?

Carriers in dependent Claims 4 and 15 are broad

Claim 4 lists: water, lactose, glucose, sucrose, starch, cellulose derivative, gelatin, oil, polyethylene glycol, physiologically compatible solvent, or combinations.
Claim 15 similarly lists carrier selection (dependent on Claim 10).

This is formulation-flexible on solids and vehicles. The constraints that matter most are typically the peptide dose range, buffer type (for narrower claims), and isotonicity agent choice (for narrower claims).

Do the claims cover different administration routes and dosage regimens?

Administration routes: broad in Claim 16; subcutaneous emphasized in Claim 9 and Claim 21/28/29 family

Claim 9: Claim 1 composition is subcutaneously injectable
Claim 16: Claim 10 composition formulated for IV, intraperitoneal, subcutaneous, IM, oral, topical, transmucosal
Claim 21: Claim 10 formulated to be subcutaneously injectable
Claim 28: Claim 22 subcutaneously injectable
Claim 29: explicitly “subcutaneously injectable pharmaceutical composition”

Practically, subcutaneous coverage is strongest because multiple claims converge on it.

Single vs divided daily dose: expressly claimed

Claims 5–8, 11, 18–20, and 25–27/30–32 cover:

single daily dose, or
divided daily dose,

with the same dose range constraints attached in the parent claims. This can matter if a product’s regimen uses twice-daily or titrated dosing that changes the “per day” peptide amount.

How does the claim set stratify into narrow vs broad infringement targets?

Coverage ladder (from broadest to narrowest based on your provided claims)

Broadest

Claim 1: SEQ ID NO. 2 peptide dose 0.001–1 mg/70 kg + generic pharmaceutically acceptable buffer/isotonicity/carrier

Medium

Claim 10: same peptide dose range + isotonicity restricted to explicit list (includes polyols, sodium chloride, dextrose, etc.)

Narrow

Claim 2 + 3: acetate buffer and mannitol/sorbitol combinations (dependent embodiments)
Claim 22: acetate buffer + mannitol/sorbitol + dose range + peptide sequence
Claim 24/27: adds dosing single/divided and a slightly different lower bound phrasing (still 0.001–1 mg/70 kg)

Most narrow

Claim 29: subcutaneous + acetate buffer + mannitol/sorbitol + aqueous carrier + peptide dose range

Patent landscape mapping: where does US 7,521,423 fit and what are typical competitive risks?

Landscape posture based on claim language: formulation-excipient and dose-range perimeter

US 7,521,423 reads like a “composition/formulation” patent that targets:

specific peptide sequence (SEQ ID NO. 2),
dose range expressed per 70 kg,
and common parenteral excipient sets (acetate buffers, mannitol/sorbitol polyols).

That posture creates two litigation vectors:

Product-identity vector: whether the competitor uses the claimed peptide identity (SEQ ID NO. 2) and falls inside the dose range.
Formulation vector: whether buffer and isotonicity agents match the narrower dependent claims, or whether the competitor uses different excipients and attempts to avoid those dependent claim limitations.

Common design-around patterns (in generic and reformulation contexts)

Within the space defined by your claims, a competitor typically tries to:

alter buffer system away from acetate (to avoid Claims 2/14/22/29),
alter isotonicity away from mannitol/sorbitol (to avoid Claims 3/13/22/29),
or adjust dosing outside the 0.001–1 mg per 70 kg range.

However, the presence of Claim 1 with open-ended buffer/carrier/isotonicity categories means that a competitor cannot assume design-around by excipient change alone if Claim 1’s broad wording still encompasses the formulation.

What patent strength signals exist inside the claims you provided?

Stronger signals

Multiple dependent claims converge on the same excipient pair: acetate buffer + mannitol/sorbitol.
Subcutaneous injection is explicitly claimed, increasing relevance to real therapeutic delivery.
The explicit dosing range provides a measurable infringement trigger.

Potential weakness signals (claim construction and product practice)

“Based on a 70 kg patient” can be litigated around dose calculation per unit, regimen, and labeling. If a competitor can argue their dosing amounts never map into the claimed range (as administered), they may reduce risk.
Carrier is broadly defined; excipient-based design-around may not help against Claim 1 if a broad “pharmaceutically acceptable carrier” is still used.

Competitive and regulatory implications: what does this mean for generic or reformulation entry?

FDA regulatory status mapping (what can be inferred from claim type)

Because the claims are composition-defined for a peptide drug product, the typical regulatory risk scenario is:

A competitor’s ANDA pathway is not typical for peptides, but a biosimilar pathway may apply depending on the exact regulatory classification of the exendin-4 product.
Regardless of pathway, the clinical product will be evaluated for formulation similarity, and formulation differences that target the dependent limitations (acetate buffer, mannitol/sorbitol, aqueous carrier, subcutaneous) are likely to be central to an infringement analysis.

Settlement leverage: excipient and dose-range switching can be bargaining chips

Given the convergent dependent claims, licensing/settlement discussions in practice often hinge on:

whether the competitor’s formulation can be engineered to avoid acetate buffer or mannitol/sorbitol,
and whether dosing regimen avoids the claimed per-70-kg range.

How many claims are likely to be infringed in typical “at-risk” products?

Based only on your claim set, infringement likelihood tends to stack:

If the competitor uses SEQ ID NO. 2 exendin-4 and peptide amount in 0.001–1 mg per 70 kg: Claim 1 and Claim 10 are baseline.
If buffer is acetate: you implicate Claims 2/14 and the narrowed Claim 22/29 line.
If isotonicity uses mannitol/sorbitol: you implicate Claims 3/13 and further narrow Claims 22/29.
If product is subcutaneous injectable: you implicate Claims 9/21/28/29.
If regimen includes single or divided daily dosing: you implicate Claims 5/6/7/11/18/19/25/26/31/32 depending on schedule.

Claim-by-claim matrix (infringement “trigger” view)

Claim	Structural requirement emphasized	Practical infringement trigger
1	SEQ ID NO. 2 peptide dose 0.001–1 mg/70 kg + buffer + isotonicity + carrier (open)	Any formulation using claimed peptide identity and peptide dose range
2	Claim 1 buffer = acetate	Any acetate-buffered variant within dose range
3	Claim 1 isotonicity = mannitol/sorbitol/polyol	Any mannitol/sorbitol isotonicity within dose range
4	Carrier selection list (open but defined)	Less likely to avoid if standard vehicles used
5	Single or divided daily dose	Any daily regimen mapping to claim dose
6–8	single vs divided + dose range variant	Schedule-specific infringement
9	subcutaneously injectable	Route-specific infringement
10	Claim 1 but isotonicity limited to explicit list	Avoidable only if isotonicity not in list (or outside “polyol” definition)
11–13	dose schedule + isotonicity polyol -> mannitol/sorbitol	High-risk if mannitol/sorbitol used
14	buffer acetate	Directly narrows
15	carrier list	Broad coverage; harder to design around
16	administration route options	Broad route coverage for Claim 10 family
17	peptide forms include acid/amide	Covers terminal-form variants
18–20	single vs divided + dose range	Schedule-specific
21	subcutaneously injectable	Route-specific
22	required components: dose + mannitol/sorbitol + acetate buffer	Strongest “compositions” claim in your set
23	acid/amide forms	Covers terminal-form variants
24–27	dosing schedule and dose range	Schedule-specific
28	subcutaneous	Route-specific
29	subcutaneous + dose + mannitol/sorbitol + acetate buffer + aqueous carrier	Most specific finished-product composition
30–32	dosing schedule (single vs divided)	Schedule-specific

Key Takeaways

US 7,521,423 is primarily a formulation composition patent for exendin-4 peptide defined by SEQ ID NO. 2, with peptide dose constrained to 0.001–1 mg per 70 kg patient.
Dependent claims create strong product-specific coverage around acetate buffer and mannitol/sorbitol isotonicity, with additional narrowing to subcutaneous injectable and aqueous carrier in Claim 29.
Single vs divided daily dose is explicitly claimed, so regimen design affects infringement risk.
Claim 1 and Claim 10 create broad “baseline” coverage via open-ended excipient categories (Claim 1) and an isotonicity list (Claim 10). Even if a competitor avoids acetate/manitol/sorbitol, the broader claims can still be implicated if the formulation remains within the peptide dose range and includes acceptable buffer/isotonicity/carrier.

FAQs

1) Can a competitor avoid US 7,521,423 by switching away from acetate buffer?
Avoiding acetate may reduce risk of dependent claims tied to acetate (Claims 2/14/22/29), but Claim 1 and Claim 10 can still be implicated depending on whether their “pharmaceutically acceptable buffer” wording and the isotonicity/carrying components remain within those claim scopes.

2) Does “0.001 mg to 1 mg based on a 70 kg patient” map to per-injection dosing?
The claims express peptide amount on a per-70-kg patient basis, so infringement will turn on how the competitor’s administered dose is calculated against that standard for the claimed regimen.

3) Are mannitol and sorbitol protected even when isotonicity is defined broadly as a polyol?
Yes. The claim set explicitly covers isotonicity as a polyol (Claim 12) with dependent coverage narrowing to mannitol and/or sorbitol (Claim 13), and independent narrowing through Claims 22 and 29.

4) Does the patent cover terminal variants like exendin-4 acid and exendin-4 amide?
Yes. Claims 17 and 23 explicitly include exendin-4 acid and/or exendin-4 amide.

5) Which single claim is most relevant for subcutaneous injectable products using acetate + mannitol/sorbitol?
Claim 29, because it requires subcutaneously injectable formulation plus the acetate buffer + mannitol/sorbitol + aqueous carrier combination with the SEQ ID NO. 2 peptide dose range.

References

No external sources were provided or cited in the prompt, and no additional patent bibliographic details (publication number, assignee, filing/priority dates, prosecution history, or listed related patents) were included.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0996459	⤷ Start Trial	CA 2007 00034	Denmark	⤷ Start Trial
European Patent Office	0996459	⤷ Start Trial	91342	Luxembourg	⤷ Start Trial
European Patent Office	0996459	⤷ Start Trial	C00996459/01	Switzerland	⤷ Start Trial
European Patent Office	0996459	⤷ Start Trial	0790031-9	Sweden	⤷ Start Trial
European Patent Office	0996459	⤷ Start Trial	464	Finland	⤷ Start Trial
European Patent Office	0996459	⤷ Start Trial	SZ 31/2007	Austria	⤷ Start Trial
Austria	304864	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,521,423

Summary for Patent: 7,521,423